Results 21 to 30 of about 3,573 (200)
Cell Reports, 2020 Summary: Calcitonin-gene-related peptide (CGRP) plays a key role in migraine pathophysiology. Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the ...
Fernando Garces +7 more
doaj +1 more source
BMC Neurology, 2021 Background Erenumab is a calcitonin gene-related peptide (CGRP)-receptor antibody inhibiting CGRP function. CGRP is prominently involved in the pathophysiology of migraine through nociceptive modulation in the trigeminovascular system. This study aims to
Bui Bao Khanh Dinh +3 more
doaj +1 more source
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
The Journal of Headache and Pain, 2018 Background Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM).
Todd Schwedt +15 more
doaj +1 more source
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study
The Journal of Headache and Pain, 2022 Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenumab with topiramate in patients who
Marc Ehrlich +4 more
doaj +1 more source
11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches : Rome, Italy. 01-03 December 2017 [PDF]
, 2017 . Aims of the study were explore the relationship between peripheral chromatic and central visual dysfunction evaluating also the presence of functional receptor impairment in patients with migraine, with and without aura examined ...
Brighina, F +5 more
core +1 more source
Early use of erenumab in US real-world practice
Cephalalgia Reports, 2021 Background: Erenumab, a monoclonal antibody (mAb) developed to block the calcitonin gene-related peptide (CGRP) receptor, is approved for the prevention of migraine in adults. This retrospective observational study sought to describe early real-world use
Alina Bogdanov +7 more
doaj +1 more source
Erenumab is effective in reducing migraine frequency and improving physical functioning [PDF]
, 2018 no abstract ...
Martelletti, Paolo
core +1 more source
Erenumab aooe: a milestone for the preventive treatment of migraine [PDF]
, 2020 Migraine is a complex neurological condition, which can affect the whole body and can result in many symptoms as nausea, vomiting, photophobia (Increased sensitivity to light), phonobhobia (Increased sensitivity to sound) and osmophobia (Increased ...
Chandra, Akash +4 more
core +2 more sources
Triptans and CGRP blockade - impact on the cranial vasculature [PDF]
, 2017 The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide ...
Alejandro Labastida-Ramírez +9 more
core +3 more sources
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience [PDF]
, 2023 Background Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all to total migraine freedom.
Fitzek, Mira +5 more
core +1 more source